Regeneron's Libtayo wins CHMP backing for six-weekly dosing across EU

Regeneron Pharmaceuticals has secured a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending an updated dosing schedule for its PD-1 inhibitor Libtayo (cemiplimab) across every indication in which the drug is currently approved in the European Union.

The opinion supports switching patients to a higher 700 mg dose given once every six weeks, after an initial 12-week induction phase at 350 mg every three weeks. The CHMP also backed a shorter infusion window: patients tolerating the 350 mg dose over 30 minutes at their first administration could subsequently receive it over as little as 15 minutes, cutting chair time by up to half.

What changes, and for whom

Libtayo holds EU approval across six indications, covering cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC), non-small cell lung cancer (NSCLC) and cervical cancer. The six-weekly maintenance option was already permitted for the post-surgical adjuvant CSCC indication; the CHMP's new opinion would extend that flexibility to the remaining five indications once the European Commission issues its formal decision, which is expected within the coming months.

The pharmacokinetic and pharmacodynamic modelling and simulation data that underpin the recommendation are drawn from Libtayo's existing clinical development programme rather than a new interventional trial. This is a common regulatory route for dosing-schedule variations, where established PK/PD datasets can be used to demonstrate that alternative regimens maintain adequate drug exposure. The EMA has accepted similar simulation-based submissions for other checkpoint inhibitors in recent years, signalling growing regulatory comfort with this approach.

Market and competitive context

Reducing infusion frequency is an increasingly important commercial differentiator in the crowded PD-1/PD-L1 inhibitor class. Merck's pembrolizumab (Keytruda) and AstraZeneca's durvalumab have both pursued less frequent dosing schedules, and Bristol Myers Squibb's nivolumab (Opdivo) is available in a six-weekly subcutaneous formulation in certain markets. For Regeneron and its commercial collaborator Sanofi, moving cemiplimab to a six-weekly intravenous regimen for maintenance therapy aligns the drug more closely with emerging patient and clinic preferences for fewer hospital visits.

From a payer and health system perspective, reduced chair time carries operational benefits: infusion units operating under capacity pressure have an incentive to favour agents that require less scheduled time per patient. Whether these logistical advantages translate into meaningful share gains against established competitors will depend on local formulary dynamics and reimbursement frameworks, which vary substantially across EU member states.

Regeneron has described oncology as the largest component of its pipeline by asset count, with checkpoint inhibitor combinations featuring prominently. Libtayo serves as the backbone for a number of investigational combinations involving bispecific antibodies, and maintaining a competitive dosing profile for the monotherapy anchor is strategically important to that broader programme.

The European Commission's formal approval decision is anticipated in the coming months and would trigger label updates across EU member states. No changes to the US prescribing information are implied by this CHMP opinion, and Regeneron did not announce any alterations to Libtayo's approved US dosing at this time.